B+
Bull case
25%
Probability
Target price
$58.80
Analysis reference price unavailable
Analysis 2026-01-31 · RankAlpha Sentiment AI
RPRX
RoyaltyDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
55%
Probability
Target price
$46.34
Analysis reference price unavailable
Analysis 2026-01-31 · RankAlpha Sentiment AI
B-
Bear case
20%
Probability
Target price
$38.00
Analysis reference price unavailable
Analysis 2026-01-31 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-01-31
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+41.3
Score
AI commentary
Market/consensus snippets show a mild positive tilt: multiple sources place the average 12-month target above the current anchor, indicating analyst upside (median ~46.34; mean ~43.45) [#SERP-1], [#SERP-7]. However coverage includes low-end estimates and at least one outlier low, producing a mixed tenor and highlighting distribution risk [#SERP-3]. Overall sentiment is cautiously constructive, contingent on royalty cash flow stability and acquisition execution.
RankAlpha Sentiment AI - 2026-01-31
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-04-30catalystFY/Quarterly results and guidance updateHigh impact
Company quarterly/FY results can reprice consensus and dividend/royalty guidance; assumed reporting window not explicit in sources so a conservative short-date is used. Assumed date: 2026-04-30 (conservative) [#SERP-5].
2026-06-30eventMajor portfolio acquisition or dispositionHigh impact
Large royalty acquisitions/dispositions materially change NAV and leverage; no firm public date available so pick window end and note assumption: assumed event end date 2026-06-30 (conservative estimate) [#SERP-1], [#SERP-3].
2027-01-31catalystAnalyst re-rating from updated consensus and macro/interest-rate tailwindsHigh impact
Analyst coverage and consensus 12-month targets can re-rate the stock over a longer window; assumed date (long horizon): 2027-01-31 (conservative 12-month horizon). Comparison/consensus fragments cited in sources [#SERP-1], [#SERP-7].
Recommendation
N/A
No formal recommendation provided.
As of 2026-01-31 • Updated nightlySource: Internal modelMethodology